Founded in 2011 by Dr. Marcus Martin (CEO) and Dr. Eddilisa Martin (President), 2M Clinical is led by a diverse team of experts with extensive hands-on experience in every aspect of clinical trials and research. Our collective knowledge of the pharmaceutical and healthcare sectors and substantial work with regulatory bodies makes us a powerful ally and smart strategic partner.
Founder & CEO
Dr. Marcus Martin has more than 25 years of experience and training in epidemiology and outcomes research. He is responsible for 2M’s corporate vision, strategic growth, and talent acquisitions. Dr. Martin is a first-generation college graduate who attended college on a football scholarship at the University of Louisiana at Monroe.
Dr. Martin received his PhD from Howard University with concentrations in Sociology and Applied Statistics and his MPH from the University of North Texas Health Science Center School of Public Health with concentrations in Population Health and Epidemiology. Dr. Martin also received a Master of Arts and his undergraduate Degree from the University of Louisiana. He is a former faculty member at the University of Oklahoma and has a current adjunct faculty appointment in the School of Public Health at the University of North Texas Health Science Center. Dr. Martin’s vision for 2M Clinical developed after the unexpected death of his 22-year-old brother in 1997 and his success in helping a close family member enroll in a clinical trial that saved her life in 1997. Twenty-five years later, that family member is one of the longest living patients ever enrolled in this still ongoing clinical trial.
Dr. Martin is the author of an upcoming memoir that is scheduled to be released on October 2, 2021: The Biggest Dreams in the Neighborhood. The book focuses on life lessons Dr. Martin learned as a poor black kid growing up in a small, shotgun-style house in Southern Louisiana. Despite his family’s meager resources while he was growing up and his early academic struggles, Dr. Martin believes he had a perfect childhood even while living in imperfect conditions—because he always managed to have the biggest dreams in the neighborhood.
His success as an athlete, academic, and entrepreneur has been developed and defined more often by failures than success. However, Dr. Martin believes failure is success—especially for a young person starting off at the bottom with absolutely nothing to lose.
At the age of 52, Dr. Martin’s remaining life’s goal is to help support efforts that will create equitable and healthy communities in America and increase the pipeline of minority entrepreneurs in America.
Everyone deserves an opportunity to enroll in a clinical trial regardless of race, gender, age, geography, or socioeconomic status.
- MM -
Dr. Eddilisa Martin has over 25 years of clinical and health outcomes research and executive leadership experience. Her research expertise is in clinical research, pharmacoeconomics, and comparative effectiveness research. She has served as a therapeutic expert across several areas, including cardiovascular disease, diabetes, oncology, immunology, and anti-infective pharmacology.
Dr. Martin also has extensive experience interfacing with providers (hospitals, physicians, ancillary providers) to improve healthcare outcomes, healthcare service utilization, and costs. Prior to her leadership role with 2M, Dr. Martin served as a national medical liaison with Abbott Labs for 19 years. She received her Doctor of Pharmacy Degree from the University of Oklahoma Health Science Center and her Bachelor of Pharmacy Degree from the University of Arkansas Medical Sciences Center. She is licensed to practice pharmacy in the states of Texas and Arkansas.
We want all patients to be able to make healthcare decisions based on clinical research data that reflects them.
- EM -
Vice President & Chief Scientific Officer
Dr. Craig Reist is a Senior Clinical Trialist with over 25 years of experience working on Pharma-sponsored global outcomes trials with a focus on using metric-driven operational strategies. Part of his expertise includes transforming and optimizing trials through an evidence-based operations model. Before joining 2M Clinical, Dr. Reist served as the Director of Megatrials at Duke University Clinical Research Institute (DCRI).
The DCRI Megatrials domain designs and operationalizes large global commercial clinical trials focused on evaluating new drugs/devices for regulatory approval. Dr. Reist oversaw these projects working closely with senior clinical and operational executives at global pharmaceutical companies to create and ensure delivery of trial operational plans. He was instrumental in helping DCRI’s Megatrials team complete over 30 global megatrials, enrolling more than 350,000 participants at thousands of sites in countries around the world. The results of these pivotal trials led to regulatory submission for label approval or expansion. Dr. Reist received his BS in Biology from Syracuse University and his PhD in biochemistry from the University of Virginia.
COVID-19 is forcing our industry to accelerate innovation with the result being a new blueprint of what is possible when managing clinical trials.
- CR -
Vice President & Chief Growth Officer
Mr. Keith Tode brings extensive subject matter expertise in consulting on corporate and commercial strategy, digital health, patient centricity, clinical trial diversity, business development, and sales management. Prior to joining 2M Clinical, Mr. Tode served in numerous leadership positions for PAREXEL International, Thomson Reuters IP & Science, and MCRA, LLC.
He managed a global portfolio of pharmaceutical and medical device clients supporting IND, NDA, 510(k), de novo and PMA submissions, clinical protocol development, market access, HEOR, real-world evidence strategy, data analytics, and virtual/hybrid clinical trials. Mr. Tode has also formed strategic partnerships and alliances with the FDA, NMPA (formerly known as China FDA), the China Insurance Regulatory Commission, and the Indian Ministry of Health while conducting business in over 40 countries worldwide. Mr. Tode received his Bachelor of Arts in Political Science from the University of New Hampshire and his MBA in International Finance from Norwich University.
Adopting a robust clinical trial diversity strategy not only makes sense scientifically, but also in terms of commercial success for sponsors.
- KT -
Chief Technology Officer
Mr. Dustin Arnold is a software architect, developer, and executive with deep technical and business experience in product and platform development. He is a business-minded technologist with a passion for leading 2M’s efforts to use cutting edge tools and technologies to drive our business success.
Early in his career, he was a co-founder of Skywire Software, where he led the delivery of software and technology for nonprofit, insurance, and financial service clients. Since then, he has been responsible for the design and delivery of software for the public and private sector, including systems used by most of the Fortune 500 companies. Mr. Arnold has significant recent experience in software, data, and cloud technology for the healthcare industry. Utilizing data across provider networks, insurers, and brokers, their systems provided healthcare navigation services to consumers, saving money and improving the quality of healthcare for patients.